69 results about "Soluble antigen" patented technology

The present invention discloses a kind of immunogical chromatographic paper strip for sensitive, specific and fast detection of common pathogen and toxin in food and the detection method. The present invention is the new technology for detecting pathogen and toxin in food and its application. Now, there are great amount of reports on applying colloidal gold immunogical chromatographic test paper in detecting soluble antigen and bacteria as granular antigen are detected after being treated via extraction or other processes. The present invention features that special chromatographic film and optimized conditions are adopted so that the immunogical chromatographic paper strip may be used directly in detecting bacteria. The present invention may be used in the fast detection of common pathogen in food and the fast diagnosis of toxin in food.

The invention discloses a hybridoma cell line of a monoclonal antibody against African swine fever virus and the secreted monoclonal antibody thereof. The preparation method of the invention comprises the following steps: preparing a recombined P30 soluble antigen by prokaryotic expression; immunizing a BALB/c mouse; and finally fusing, screening and cloning by a hybridoma technology to obtain the hybridoma cell line which can stably secrete the monoclonal antibody against African swine fever virus P30 protein. The invention further discloses a method for preparing the monoclonal antibody with the cell line, an antibody purification method and a labeling method for horseradish peroxidase of the antibody. The monoclonal antibody can be used in detecting the African swine fever viral antibody in pig serum.

The invention relates to model systems for allergic conditions, and in particular to in vivo model systems in a large animal. The model systems of the invention are especially useful for providing large numbers of activated or non-activated eosinophils, for the discovery and evaluation of novel anti-inflammatory drug targets and for providing a model for the in vivo study of asthma and the effects of allergy treatments. In a preferred embodiment the animal is a sheep. In one embodiment, repeated infusion of house dust mite allergen (HDM) into the mammary gland is used to induce a specific allergic response, which is characterised by the recruitment of inflammatory cells, particularly eosinophils, into the mammary lumen; these cells can be harvested from peripheral blood and mammary lavage (MAL). In a second embodiment, the mammal is immunised with soluble antigen, for example by repeated subcutaneous immunisation, and then subjected to a single challenge with the same antigen administered directly to the lung.

The invention discloses an immunochromatographic strip for detecting viscerotropic leishmania infection and diagnosing kala-azar, which comprises a sample pad, a conjugate pad which is closely connected to the sample pad and contains a colloidal gold-labeled probe, a cellulose membrane closely connected with the conjugate pad and a water absorption pad closely connected to the cellulose membrane. The water absorption pad is far away from the conjugate pad, a quality control line is arranged at one end of the cellulose membrane, which is close to the water absorption pad, a detection line is positioned on the cellulose membrane between the quality control line and the conjugate pad, the detection line contains soluble antigen of the viscerotropic leishmania, and the quality control line contains antibodies specifically binding to the colloidal gold-labeled probe. The invention further provides a kit containing the immunochromatographic strip and a preparation method for the immunochromatographic strip. The immunochromatographic strip has the advantages of being simple and convenient to use, high in sensitivity and specificity, fast in detection, and simultaneously applicable to clinical and field use for human, livestock and wild animals.

The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.

The invention discloses a fresh water fish liver fluke fast immunity test kit and a test method. The kit box comprises an enzyme linked reaction board, an enzyme conjugate, washing liquid, a substrate solution, a color developer, a diluent and an end solution, wherei the enzyme linked reaction board is made by extracting and purifying soluble antigen from liver fluke and enveloping the soluble antigen; the enzyme conjugate is made by labeling anti-fish immunoglobulin via horseradish peroxidase. The invention utilizes the sensitivity, the specificity, the practicality and the economy of the fast immunity test technique to establish a fresh water fish liver fluke fast immunity test method, is practical and simple while the kit can be opened and used instantly, without preparation or dilution, with simple operation; the result can be judged quantitatively by instruments and can be judged by eyes, thus is suitable of the on-site detection of different conditions; the invention is safe and environment friend, which adopts the harmless enzyme linked immunity color developer as tetramethylbenzidine to avoid the harm and pollution of general methods.

An improved assay is described where a surface is provided with immobilized anti-Ig antibodies rather than antigen and where specific antibody-secreting cells (ASC) are detected using soluble antigen probes containing one of several possible labels. The method gives improved sensitivity with less background and is also more representative because antigen binding does not employ immobilized antigen. The assay is particularly effective for measuring antibody secreting cells against HIV, for determining whether an infection is acute as opposed to old or latent, for mapping epitopes and for measuring for ASCs against different antigens in the same reaction.

A dual-antibody sandwith ELISA detecting method for human soluble p185HER-2 antigen features that the purified and coated P185HER-2 monoclonal antibody is bound to solid supporter, the specimen containing soluble p185HER-2, the purified standard p185HER-2 antigen and the coated antibody are incubated, and another purified and coated p185HER-2 monoclonal antibody marked by horseradish perioxidase is used as detecting antibody. It can be used for serum diagnosis of tumor.

The invention relates to a gold-labeled kit for detecting angiostrongylus cantonensis disease and a preparation method thereof. The method comprises the preparation of angiostrongylus cantonensis soluble antigen, the preparation and purification of monoclonal antibodies, the preparation of colloidal gold-labeled anti-angiostrongylus cantonensis monoclonal antibodies, and the preparation of an angiostrongylus cantonensis gold-labeled rapid diagnosis kit. The kit comprises an angiostrongylus cantonensis gold-labeled detection plate; the detection plate comprises a PVC liner plate, an absorbent pad, a gold-labeled pad which is coated by colloidal gold-labeled angiostrongylus cantonensis monoclonal antibodies, a detection line which coats angiostrongylus cantonensis monoclonal antibodies inside and a quality control line of goat anti-mouse IgG or IgM. The kit is simple and rapid in operation, requiring only 5 to 15min; the kit has high sensitivity and strong specificity, and the detection rate of the rat serum which is experimentally infected by angiostrongylus cantonensis and the detection rate of the angiostrongylus cantonensis patient serum are both 100 percent. The kit and the preparation method can play an important role in rapid diagnosis and efficacy assessment of angiostrongylus cantonensis.

The invention discloses an enzyme immunological method of rapidly detecting the antibody of the measles virus, mainly using PEG to speed up the antigen-antibody reaction, thus shortening the reactiontime of routine ELISA. Firstly, wrap the soluble antigen in the enzyme-mark board; secondly made up the PBS lotion, PH9.6, and the sample diluent containing PEG; thirdly use the sample diluent to dilute the measured blood serum and the positive and negative comparison blood serum, fourthy add the diluted blood serum into the hole of the enzyme-mark board for warm cultivation; fifthly throw off the antigen solution in the hole, and use PBS lotion to wash; sixthly use the sample diluent to dilute the known enzyme-mark antibody; seventhly add the diluted enzyme-mark antibody in the hole for warmcultivation.

The invention discloses a method for preparing a magnetized and hydroformyled sheep red blood cell. The method comprises the following steps of: preparing nano magnetic beads; preparing a hydroformyled sheep red blood cell; preparing a magnetized and hydroformyled sheep red blood cell; coating protein on the magnetized and hydroformyled sheep red blood cell; detecting a sample; and observing the result. The prepared magnetized and hydroformyled sheep red blood cell can be used as an indicator cell of an agglutination test, a carrier, enzyme and a chemiluminescence matter of an antigen antibody agglutination test, or a carrier detected in a fluorescent material marking test. The magnetized and hydroformyled sheep red blood cell prepared by the method is long in retention period, simultaneously has paramagnetism, can achieve rapid aggregation and redispersion, avoids complicated centrifuge processes in the traditional agglutination test, and can be used for preparing artificial granular antigen antibodies with uniform sizes; coating and detection reaction are carried out in a uniform phase after a solid-phase carrier is replaced; and the method is full in action, high in sensitivity, low in cost than an elisa plate, and is mainly applied to a screening or quantitative detection test of a special red blood cell antibody and other soluble antigen antibodies.

This application discloses methods, systems and kits for correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. Tolerance can be induced by solo or repeated administration of antigen, including soluble antigens administered either intravenously or sublingually. This application also discloses methods for detecting variants. In addition the application addresses the use or avoidance of non steroidal anti inflammatory drugs in therapy.

The invention discloses a hydatidovis soluble antigen preparation method and a product thereof. The preparation method comprises: expressing gene represented by SEQ ID No.1, SEQ ID No.3 or SEQ ID No.5 in an insect bioreactor or a pichia pastoris bioreactor; and collecting and purifying the antigen to obtain the hydatidovis soluble antigen. In the method disclosed by the invention, a domestic silkworm bioreactor or the pichia pastoris bioreactor is used to prepare the hydatidovis antigen, the product is soluble, immune experiments prove the antigen has high antigen performance, the unit expression is 10 to 100 times higher than that of Escherichia coli, and animal experiments prove the antigen has high insect reducing efficiency. When the method is used, the production cost of the hydatidovis antigen can be reduced greatly, and the purification process of the conventional production of antigen by Escherichia coli is simplified; and the method has the advantages of safety, high efficiency, low cost and the like.

The field of the invention relates in general to at least one method and apparatus for the production of soluble MHC antigens and more particularly, but not by way of limitation, to at least one method and apparatus for the production of soluble Class I and II HLA molecules. The field of the invention also includes such produced soluble Class I and II HLA molecules and their use. According to the methodology of the present invention, the soluble Class I and II HLA molecules can be produced from either gDNA or cDNA starting material.

The invention discloses a method for preparing a proteus mirabilis-staphylococcus aureus-pseudomonas aeruginosa adsorption combined vaccine. The method includes the steps that firstly, a proteus mirabilis culture solution is subjected to in-situ digestion, high-speed centrifugation, pre-filtering, ultrafiltration and precipitation, and a proper proteus mirabilis cell membrane soluble antigen raw solution is obtained; secondly, a staphylococcus aureus bacterium suspension is subjected to centrifugation, smashing, re-centrifugation, filtering, precipitation, enzymolysis and dialysis, and a proper staphylococcus aureus cytoplast antigen raw solution is obtained; thirdly, a staphylococcus aureus and pseudomonas aeruginosa culture solution is subjected to centrifugation and pre-filtering, formalin is added for detoxification, then purification is conducted, and a proper inactivated staphylococcus aureus and pseudomonas aeruginosa toxin raw solution is obtained. The vaccine is used for preventing burn, scalding and infection caused by one or more of conditioned pathogens including proteus mirabilis, staphylococcus aureus and pseudomonas aeruginosa before and after operations in an intramuscular deep injection mode.

The invention discloses an adjuvant for improving immersion immunization effect of fishery vaccines and an application of the adjuvant. The adjuvant is castor oil polyethylene glycol monoester glucoside or a composition of castor oil polyethylene glycol monoester glucoside, azone and anisodamine. The application of the adjuvant comprises the following steps: dissolving an appropriate amount of adjuvant into water and then uniformly mixing with a vaccine solution in certain volume ratio, putting to-be-immune fishes into the mixed solution, filling gas and soaking for 15-30 minutes. According to the adjuvant disclosed by the invention, the castor oil polyethylene glycol monoester glucoside has good effects of biodegradability, non-toxicity, low interface tension, good water solubility, effects of dispersing, emulsifying and the like, so that oils or in-soluble antigens which are not dissolved in water are uniformly dispersed, and the immune effects of the vaccines are effectively improved. The application method of the adjuvant is simple, safe to apply, environment-friendly and free of adverse interferences on growth of fishes in culture production.

The invention relates to an immunochromatographic test strip for rapid detection of ancylostomiasis infection. The test strip includes: a sample pad, a gold labeled pad that is closely connected to the sample pad and contains a colloidal gold labeled probe, a cellulose membrane closely connected to the gold labeled pad and a water absorption pad closely connected to the other end of the cellulose membrane. One cellulose membrane end far from the gold labeled pad is provided with a quality control line, the cellulose membrane between the quality control line and the gold labeled pad is equipped with a detection line, which is composed of a hookworm purification worm antigen, and the hookworm purification adult worm antigen is a soluble antigen solution of Necator Americanus adult worms. The colloidal gold labeled probe is staphylococcus aureus A protein or s streptococcus G protein. The control line is composed of the antibody specifically binding with the colloidal gold labeled probe. The invention also provides a preparation method of the immunochromatographic test strip. The immunochromatographic test strip provided by the invention has the advantages of simplicity, sensitivity, specificity and rapidity, and can be applied to clinical and field use of human, livestock and wild animals at the same time.

The invention provides a method for stimulating the production of antibodies to a cryptic epitope on a soluble antigen by administering to a patient having such a cryptic epitope a binding agent that binds to the soluble antigen and forming a complex between the binding agent and the soluble antigen, wherein the cryptic epitope is exposed and the patient generates antibodies that bind to the cryptic epitope.